Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Building Tomorrow Together: What We Are Looking Forward to at CtUC 2024

Censis Technologies previews what sterile processing and perioperative healthcare leaders can expect at the CtUC 2024 user conference. The event brings together industry professionals to explore innovation, best practices, and collaboration in sterile processing. Attendees can expect sessions focused on shaping the future of perioperative care through technology and shared expertise.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Censis on MarketScale.

By Healthcare · Censis TechnologiesCensis Technologies Users Conference 2024Harshil GoradiaShena Moore
Share

Key takeaways

01

CtUC 2024 is a user conference hosted by Censis Technologies focused on sterile processing and perioperative healthcare.

02

The event emphasizes collaboration among sterile processing leaders to drive innovation and best practices.

03

Sessions are designed to help healthcare facilities advance their use of Censis technology and improve patient safety outcomes.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Get ready for the event of the year—Censis Technologies Users Conference 2024! This groundbreaking conference is where the sterile processing community comes together to ignite innovation, build powerful connections, and elevate healthcare to new heights. If you're a technician, manager, or industry expert within the perioperative loop, this is the must-attend event of the year! With the theme, "Building Tomorrow: Innovate, Empower, Thrive," CtUC 2024 promises to be an unforgettable experience, bringing together thought leaders, cutting-edge technology, and industry-changing insights that will shape the future of healthcare.

Censis Technologies' leadership is thrilled about what this year's conference will offer. In this episode of ConCensis, host Gabrielle Bejarano sat down with Sheena Moore, the President of Censis Technologies, Yizhou Chen, the VP of Product and Marketing, and Harshil Goradia, the Chief Technology Officer.

Sheena Moore is gearing up for her first-ever CtUC, and she's fired up about the potential this event holds. For her, CtUC 2024 is all about learning from clients and pushing the boundaries of innovation. This is your chance to be part of something bigger, where new technologies will be unveiled, challenges will be tackled head-on, and the focus will remain on the ultimate goal: delivering superior patient care across the globe.

This is your chance to be part of something bigger, where new technologies will be unveiled, challenges will be tackled head-on, and the focus will remain on the ultimate goal: delivering superior patient care across the globe.

Yizhou Chen is excited to dive into the heart of what makes Censis tick—its customers. At CtUC 2024, you'll experience firsthand how Censis collaborates with its clients to create solutions that don't just meet the present needs but anticipate the future. Innovation isn't just a buzzword here—it's the driving force behind every product and service. Expect to leave CtUC 2024 with new insights, tools, and a network that empowers you to solve problems, improve workflows, and enhance patient outcomes like never before.

Expect to leave CtUC 2024 with new insights, tools, and a network that empowers you to solve problems, improve workflows, and enhance patient outcomes like never before.

Harshil Goradia promises that CtUC 2024 will put innovation in the spotlight, especially with AI and advanced technologies that are transforming the sterile processing industry. With a commitment to accelerating product development and enhancing customer support, Censis is leading the charge in revolutionizing healthcare. Don't miss your chance to be a part of this exciting journey, where cutting-edge technology meets real-world application, and where you'll walk away empowered to make a real impact in your organization. CtUC 2024 is set to be a game-changer—be there to witness it!

Censis

Part of this channel

Censis

Surgical instrument management software for over 1,300 U.S. hospitals.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

H
Healthcare

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

Interchangeable biosimilars are getting approved faster, and Wezlana shows why

The FDA approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for multiple inflammatory diseases, which means it may be substituted without consulting the prescriber, subject to state pharmacy laws. A Springer analysis reported 26 interchangeable biosimilars approved since 2020 and said average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024. The operational pressure shifts to formulary, payer, and specialty pharmacy workflow design.

  • 01Interchangeability is becoming the default ask, not an afterthought: Springer found 17 of 26 approvals pursued interchangeability concurrently, which changes how buyers should time contracting and conversions.
  • 02Springer reported average approval timelines decreased from 798 days for applications dated in 2020 to 364 days for applications dated in 2024, which can compress planning windows for monitoring and implementation.
  • 03A new interchangeable ustekinumab option means the hard work is no longer clinical, it is operational: NDC mapping, EMR preference lists, substitution rules by state, and patient communications decide whether savings show up.

Sep 8, 2026

AAO-HNSF hearing loss guideline moves audiograms and amplification into primary care

AAO-HNSF’s new age-related hearing loss guideline calls for screening adults starting at age 50 and escalating to otoscopy, audiogram, and appropriately fit amplification. It shifts hearing loss from “patient complaint” to a routine primary-care workflow. The pressure shows up in audiology capacity, referral design, and documentation standards.

  • 01Screening at age 50 becomes a repeatable workflow, so capacity planning shifts from episodic ENT referrals to steady primary-care volume, especially where annual wellness visits are a dominant access point.
  • 02The guideline’s escalation sequence, screen, otoscopy, audiogram, amplification, then cochlear implant candidacy evaluation, creates a measurable funnel that health systems can instrument in the EHR and manage like any other pathway.
  • 03Asymmetric loss remains a separate trigger for MRI in many settings, and 2026 pre-proof work using NHANES and SEER highlights why imaging criteria choices can swing scan volume, a budgeting and radiology access issue, not a clinical footnote.

Sep 7, 2026

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

ADHA shifts My Health Record to multi-supplier ops as Accenture signs new 3-year contract

Accenture will keep supporting Australia’s My Health Record under a new three-year contract. ADHA is moving the platform to a multi-supplier operating model. The shift raises questions about shared integration discipline, tooling, and accountability when changes hit production.

  • 01Multi-supplier delivery is spreading across national-scale health platforms, as ADHA's My Health Record shift shows, moving risk from vendor selection to integration, runbooks, and accountability.
  • 02GenAI model upgrades are arriving with healthcare-specific claims, but the procurement work moves to evidence, safety controls, and monitoring once models sit inside clinical workflows.
  • 03Embedded AI expands the cyber asset inventory problem: if teams cannot discover the AI components across endpoints and devices, they cannot reliably secure or audit them.

Sep 7, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

H
Healthcare

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512